Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05916469 · ClinicalTrials.gov registry record
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
A clinical trial of Heavy Menstrual Bleeding and Von Willebrand Diseases, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 300
- Enrollment target
- 9
- Study locations
NCT05916469: Recruiting study of Heavy Menstrual Bleeding and Von Willebrand Diseases, sponsored by Oregon Health and Science University.
NCT05916469 is a study of Heavy Menstrual Bleeding and Von Willebrand Diseases that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 300 participants, above the 192-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (56% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05916469, a study of Heavy Menstrual Bleeding and Von Willebrand Diseases, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application the study will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.
Primary Outcome
Proportion with pictorial blood loss assessment score \<50 points
Conditions Studied
Interventions
- DRUG Levonorgestrel Intrauterine System
- DRUG Norethindrone Acetate
Study Locations (9)
Washington
- University of Washington - Seattle
- Seattle Children's Hospital - Seattle
California
- Stanford - Palo Alto
Colorado
- Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory - Atlanta
Michigan
- University of Michigan Medicine - Ann Arbor
Missouri
- Children's Mercy - Kansas City
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Penn State Health - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2029-06 |
What NCT05916469 shows while recruiting
NCT05916469 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (56% higher).
The record links to 3 conditions, with Heavy Menstrual Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Levonorgestrel Intrauterine System is the first listed.
NCT05916469 lists 9 locations in 8 states (Washington, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05916469 about?
NCT05916469 is a clinical study titled "Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study". The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of ...
What is the current status of trial NCT05916469?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-09-24. Estimated completion is 2029-06.
What conditions does trial NCT05916469 study?
This clinical trial studies the following conditions: Heavy Menstrual Bleeding, Von Willebrand Diseases, Bleeding Disorder.
What interventions are being tested in trial NCT05916469?
The interventions under investigation include: Levonorgestrel Intrauterine System (DRUG), Norethindrone Acetate (DRUG).
Who is sponsoring clinical trial NCT05916469?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05916469 being conducted?
This trial has 9 study locations across California, Colorado, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heavy Menstrual Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05916469's enrollment target sits among peer trials
300 3rd of 9 higher than 6 of 9 other Heavy Menstrual Bleeding trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heavy Menstrual Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
RECRUITING
-
Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)
RECRUITING · NA
-
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease
COMPLETED · NA
-
Efficacy and Safety Study of XP12B in Women With Menorrhagia
COMPLETED · Phase 3
-
Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial
COMPLETED · NA
-
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI